市场趋势
| 短期 | 中期 | ||
| 行业 | Health Information Services (US) | 混合的 | 看跌 |
| Health Information Services (全球的) | 混合的 | 看跌 | |
| 股票 | FOXO Technologies Inc. | - | - |
AIStockmoo 评分
| 价值 35% | -1.8 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -1.8 |
| 时机 35% | 3.2 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 2.0 |
| 技术平均移动指标 参考 | 5.0 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×0.94 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | +13.7% |
| 支柱一致性 | ×0.89 |
| 不计入评分 | |
| 价格波动 参考 | -1.1 |
| 最终评分 | 0.41 |
|
FOXO Technologies Inc. engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and FOXO Life, a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with the Longevity Report. The company was founded in 2020 and is based in Minneapolis, Minnesota. FOXO Technologies Inc. is a subsidiary of FOXO Management LLC. |
|
| 部门 | Healthcare |
| 行业 | Health Information Services |
| 内部持股比例 | 1.75% |
| 机构持股比例 | 0.45% |
投资组合